Big risers include Eli Lilly, Biogen, Moderna and Biontech.
Long-awaited results from the Herald study are a bust, and the data will likely deteriorate further.
But with many Western markets already saturated, it is worth wondering how important Novavax’s Covid-19 jab will become.
With a Darpin antiviral for treating Covid-19 Molecular Partners hopes to follow Vir’s regulatory path.
Instead of long-awaited phase 3 data Novavax’s first-quarter presentation reveals a Covid-19 vaccine manufacturing snafu.